Ticagrelor
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Mar 28, 2018 → May 7, 2019
NCT ID
NCT03492931About Ticagrelor
Ticagrelor is a phase 1 stage product being developed by AstraZeneca for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03492931. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03492931 | Phase 1 | Completed |
| NCT03145194 | Phase 2 | UNKNOWN |
| NCT02341729 | Approved | Completed |
| NCT02292277 | Pre-clinical | Completed |
| NCT02282332 | Approved | Completed |
| NCT02071212 | Phase 2 | Completed |
| NCT01870921 | Approved | Completed |
Competing Products
20 competing products in Sickle Cell Disease